Physician profile
Peter Klucar
NPI 1104322833
$2,303.37
in general payments reported to CMS, 2019-2025
26 companies · $2,216 in 2025
The $2,216 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.22 · 2022: $33.49 · 2025: $2,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,215.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.38 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $291.41 | 2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $159.55 | 2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $154.04 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.66 | 2025 | Jardiance |
| Lilly USA, LLC | $148.84 | 2022-2025 | Zepbound, Mounjaro |
| Axsome Therapeutics, INC. | $148.73 | 2025 | Auvelity, Symbravo |
| Novo Nordisk INC | $124.69 | 2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $94.06 | 2025 | |
| Glaxosmithkline, LLC. | $91.20 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Inspire Medical Systems, INC. | $75.27 | 2025 | Inspire |
| Corcept Therapeutics | $66.22 | 2025 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.58 | 2025 | Xifaxan |
| Collegium Pharmaceutical, INC. | $61.63 | 2025 | Jornay Pm |
| Phathom Pharmaceuticals, INC. | $57.45 | 2025 | Voquezna |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $55.96 | 2025 | Rexulti |
| Recor Medical INC | $36.51 | 2025 | Paradise Ultrasound Renal Denervation System |
| Abiomed | $31.77 | 2025 | |
| Tonix Medicines, INC. | $22.25 | 2025 | Tonmya |
| Midsouth Orthopedics INC. | $19.63 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.46 | 2025 | Quviviq |
| Ardelyx, INC. | $18.16 | 2025 | Ibsrela |
| Abbott Laboratories | $14.89 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $14.05 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.51 | 2025 | Caplyta |
| Astellas Pharma US INC | $13.47 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Klucar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.